Ruthenium Complexes in the Fight against Pathogenic Microorganisms. An Extensive Review.
Munteanu AC, Uivarosi V.
Pharmaceutics · review-article; review; journal article · DOI 10.3390/pharmaceutics13060874 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för KP1339. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
18 träffarCoordination and Redox Dual-Responsive Mesoporous Organosilica Nanoparticles Amplify Immunogenic Cell Death for Cancer Chemoimmunotherapy.
Zhang F, Chen F, Yang C, Wang L, Hu H, Li X, Zheng X, Wang Z, Chang Z, Li T, Li L, Ge M, Du J, Sun W, Dong WF, Shao D.
Small · research support, non-u.s. gov't; journal article · DOI 10.1002/smll.202100006Emerging Molecular Receptors for the Specific-Target Delivery of Ruthenium and Gold Complexes into Cancer Cells.
Machado JF, Correia JDG, Morais TS.
Molecules · review-article; review; journal article · DOI 10.3390/molecules26113153Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD-100/KP1339 in the Endoplasmic Reticulum.
Neuditschko B, Legin AA, Baier D, Schintlmeister A, Reipert S, Wagner M, Keppler BK, Berger W, Meier-Menches SM, Gerner C.
Angew Chem Int Ed Engl · brief-report; research support, non-u.s. gov't; journal article · DOI 10.1002/anie.202015962Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer.
Bakewell S, Conde I, Fallah Y, McCoy M, Jin L, Shajahan-Haq AN.
Cancers (Basel) · research-article; journal article · DOI 10.3390/cancers12092647Rhenium-Based Complexes and in Vivo Testing: A Brief History.
Capper MS, Packman H, Rehkämper M.
Chembiochem · research support, non-u.s. gov't; research-article; review; journal article · DOI 10.1002/cbic.202000117Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids.
Rusz M, Rampler E, Keppler BK, Jakupec MA, Koellensperger G.
Metabolites · research-article; journal article · DOI 10.3390/metabo9120304First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids in vitro.
Wernitznig D, Kiakos K, Del Favero G, Harrer N, Machat H, Osswald A, Jakupec MA, Wernitznig A, Sommergruber W, Keppler BK.
Metallomics · research support, non-u.s. gov't; journal article · DOI 10.1039/c9mt00051hNAMI-A and KP1019/1339, Two Iconic Ruthenium Anticancer Drug Candidates Face-to-Face: A Case Story in Medicinal Inorganic Chemistry.
Alessio E, Messori L.
Molecules · review-article; review; journal article · DOI 10.3390/molecules24101995Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
Artner C, Holtkamp HU, Hartinger CG, Meier-Menches SM.
J Inorg Biochem · research support, non-u.s. gov't; journal article · DOI 10.1016/j.jinorgbio.2017.07.010Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis.
Schoenhacker-Alte B, Mohr T, Pirker C, Kryeziu K, Kuhn PS, Buck A, Hofmann T, Gerner C, Hermann G, Koellensperger G, Keppler BK, Berger W, Heffeter P.
Cancer Lett · journal article · DOI 10.1016/j.canlet.2017.07.009Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.
Blazevic A, Hummer AA, Heffeter P, Berger W, Filipits M, Cibin G, Keppler BK, Rompel A.
Sci Rep · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/srep40966CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
Chang SW, Lewis AR, Prosser KE, Thompson JR, Gladkikh M, Bally MB, Warren JJ, Walsby CJ.
Inorg Chem · journal article · DOI 10.1021/acs.inorgchem.6b00359Molecular mode of action of NKP-1339 - a clinically investigated ruthenium-based drug - involves ER- and ROS-related effects in colon carcinoma cell lines.
Flocke LS, Trondl R, Jakupec MA, Keppler BK.
Invest New Drugs · research-article; journal article · DOI 10.1007/s10637-016-0337-8Biodistribution of the novel anticancer drug sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] KP-1339/IT139 in nude BALB/c mice and implications on its mode of action.
Bytzek AK, Koellensperger G, Keppler BK, G Hartinger C.
J Inorg Biochem · journal article · DOI 10.1016/j.jinorgbio.2016.02.037Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice.
Egger AE, Theiner S, Kornauth C, Heffeter P, Berger W, Keppler BK, Hartinger CG.
Metallomics · research support, non-u.s. gov't; journal article · DOI 10.1039/c4mt00072bLC- and CZE-ICP-MS approaches for the in vivo analysis of the anticancer drug candidate sodium trans-[tetrachloridobis(1H-indazole)ruthenate(III)] (KP1339) in mouse plasma.
Bytzek AK, Boeck K, Hermann G, Hann S, Keppler BK, Hartinger CG, Koellensperger G.
Metallomics · research support, non-u.s. gov't; evaluation study; journal article · DOI 10.1039/c1mt00055aAntiangiogenic properties of selected ruthenium(III) complexes that are nitric oxide scavengers.
Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M.
Br J Cancer · research support, non-u.s. gov't; research-article; journal article · DOI 10.1038/sj.bjc.6600906